DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company

Monthly information regarding the total number of voting rights and total number of shares of the Company

                                                                                                                                                                                                                                                                       

Monthly information regarding the total number of voting rights and

total number of shares of the Company

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
03/16/202054,927,187 



Total gross of voting rights: 54,927,187



 
 



Total net* of voting rights:  54,863,636



 

* Total net = total number of voting rights attached to shares – shares without voting rights

Attachment

EN
26/03/2020

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Positive Topline Results from Phase 3 VITES...

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria a...

7h / 59m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce des résultats préliminaires positifs dans l’é...

DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide VITESSE a atteint son critère d’évaluation principal : la limite inférieure de l’intervalle de confiance à 95 % (IC) à savoir la différence entre les taux de réponse des groupes actif et pl...

7h / 59m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights11/30/2025 200,777,718  Total gross of voting rights: 200,777,718  Total net* of voting rights: 200,667,869  * Net total = total number of voting rights at...

December 2, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions c...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date  Nombre totald’actionscomposant le capital socialNombre totalde droits de vote30/11/2025  200.777.718  Total brut des droits de vote : 200.777.718  Total net* des droits de vote : 200.667.869  *Total net = nombre t...

December 2, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Pha...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the l...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch